Other

The Cleveland Clinic Foundation

Wei Hao Xiao

Robert H Silverman

Guiying Li

Paul F Torrence

Nick Mario Cirino

Mark R Player

The present invention relates to methods of inhibiting infection by RNA viruses with complexes of an activator of RNase L and an oligonucleotide that is capable of binding to the genome, antigenome or mRNAs of a negative strand RNA virus to specifically cleave the genomic or antigenomic RNA strand of the virus. In accordance with the present invention, the methods and complexes of the invention may be applied to target any negative strand RNA virus. The invention in one embodiment relates to a covalently linked complex of an oligonucleotide that is capable of binding to the genomic or antigenomic template RNA strand of a negative strand RNA virus and/or binding to an mRNA of a viral protein (an &ldquo;antisense oligonucleotide&rdquo;) coupled to an activator of RNase L. In a preferred embodiment of the present invention, the oligonucleotide component of the complex is complementary to a region of the viral genomic RNA strand characterized by repeated or consensus sequences.

RNase L activators and antisense oligonucleotides effective to treat RSV infections

A car alarm transmitting and paging system comprising an improvement of an existing conventional phone pager and transmitter which allows the pager to be used dually as a phone pager and also as an alarm activation notification device, wherein the transmitter is used in conjunction with a conventional vehicle alarm to transmit the notification of alarm activation to the carrier of the modified pager. Because the modified pager still accepts incoming calls and operates as a conventional pager, this invention obviates the necessity of owning and carrying two separate pagers, one for normal pager use, and the other for notification of alarm activation.

Car alarm transmitting and paging system

The invention concerns a compounds and methods for treating infection with Respiratory Syncytial Virus. The compounds comprise an antisense portion, which is complementary to a normally single stranded portion of the RSV antigenomic strand (the mRNA strand), a linker and a oligonucleotide activator of RNase L, a ubiquitous non-specific RNase. The method comprised forming a complex of an activated RNase L and the antisense molecule. The application teaches methods of determining which portions of the RSV antigenomic strand are normally single-stranded. The application teaches that an antisense oligonucleotide having the sequence of residues 8281-8299 of the RSV genome is particularly useful to practice the invention and provides in vitro results superior to those obtainable with the conventional drug of choice, ribavirin.

Growing community of inventors

Rowland Heights, CA, United States of America

Wei Hao Xiao